Harmony Biosciences Holdings, Inc. (HRMY) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Harmony Biosciences reported revenue of $868.5M, up 21.5% from $714.7M the year before. Net income was $158.7M (a 18.3% net margin), or $2.71 per diluted share. Gross margin was 77.2% and operating margin was 24.0%. Operating activities generated $348.2M of cash, leaving $347.9M of free cash flow. At fiscal year end, Harmony Biosciences held $1.27B in total assets against $401.4M in total liabilities, including $752.5M of cash and equivalents.
Open the full interactive Harmony Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Harmony Biosciences Key Stats
| Share Price | $37.03 |
|---|---|
| Market Cap | $2.18B |
| P/E Ratio | 13.7 |
| Revenue YoY Growth | +21.5% |
| 52-Week Range | $25.90 – $42.86 |
| Shares Outstanding | 57.9 million (basic, 2026 Q2) |
Harmony Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Cost of Goods Sold | $27.7M | $55.5M | $83.5M | $121.2M | $156.8M | $198.3M |
| Gross Profit | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| Operating Income | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| Pre-Tax Income | -$36.9M | $37.4M | $104.7M | $173.4M | $191.8M | $215.1M |
| Income Tax | — | $2.8M | -$76.8M | $44.5M | $46.3M | $56.4M |
| Net Income | -$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| Diluted EPS | -$2.48 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |
Harmony Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $239.5M | $243.8M | $215.4M | $261.3M |
| Net Income | $50.9M | $22.5M | $32.5M | $75.4M |
| Diluted EPS | $0.87 | $0.38 | $0.55 | $1.28 |
Harmony Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $228.6M | $234.3M | $243.8M | $311.7M | $453.0M | $752.5M |
| Current Assets | $262.9M | $284.4M | $400.3M | $451.1M | $579.3M | $907.0M |
| Total Assets | $427.1M | $433.4M | $673.9M | $811.4M | $999.2M | $1.27B |
| Current Liabilities | $134.5M | $53.8M | $78.9M | $163.8M | $175.1M | $252.1M |
| Total Long-Term Debt | $194.2M | $192.0M | $191.6M | $193.6M | $179.3M | $163.7M |
| Total Liabilities | $329.9M | $246.9M | $271.0M | $344.5M | $340.0M | $401.4M |
| Shareholders' Equity | $97.2M | $186.5M | $402.8M | $467.0M | $659.2M | $870.2M |
Harmony Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.0M | $98.6M | $144.5M | $219.4M | $219.8M | $348.2M |
| Cash From Investing | -$2.0M | -$100.3M | -$141.8M | -$46.4M | -$67.5M | -$39.6M |
| Cash From Financing | $209.2M | $7.4M | $6.8M | -$105.6M | -$11.0M | -$9.0M |
| Free Cash Flow | -$3.0M | $98.3M | $144.3M | $219.1M | $218.7M | $347.9M |
Figures from Harmony Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Harmony Biosciences financials page for every line item.
Harmony Biosciences Company Profile
| Ticker | HRMY |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Plymouth Meeting, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001802665 |
Frequently Asked Questions
What was Harmony Biosciences' revenue in fiscal 2025?
Harmony Biosciences (HRMY) reported revenue of $868.5M for fiscal 2025.
What is Harmony Biosciences' annual revenue history?
Harmony Biosciences' annual revenue by fiscal year: 2020: $159.7M; 2021: $305.4M; 2022: $437.9M; 2023: $582.0M; 2024: $714.7M; 2025: $868.5M.
What was Harmony Biosciences' net income in fiscal 2025?
Harmony Biosciences reported net income of $158.7M for fiscal 2025.
What was Harmony Biosciences' earnings per share (EPS) in fiscal 2025?
Harmony Biosciences' diluted EPS was $2.71 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Harmony Biosciences generate in fiscal 2025?
Harmony Biosciences generated $347.9M of free cash flow in fiscal 2025.
What was Harmony Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Harmony Biosciences reported revenue of $261.3M.
How much debt does Harmony Biosciences have?
Harmony Biosciences reported $163.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Harmony Biosciences are outstanding?
Harmony Biosciences reported a weighted average of 57.9 million basic shares outstanding in 2026 Q2.
What is Harmony Biosciences' market cap?
Based on its latest closing price, Harmony Biosciences (HRMY) has a market capitalization of about $2.18B.
When does Harmony Biosciences' fiscal year end?
Harmony Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Harmony Biosciences headquartered?
Harmony Biosciences lists its business address in Plymouth Meeting, Pennsylvania in its SEC filings.